The nonprofit scientific research organization IAVI and Moderna, Inc. , a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced that the first participant screenings are soon to start for a phase I clinical trial of an mRNA HIV vaccine antigen (mRNA-1644) at the Center for Family Health Research (CFHR) in Kigali, Rwanda, and The Aurum Institute in Tembisa, South Africa.
The IAVI-sponsored trial, IAVI G003, builds on progress in HIV vaccine research. Recent findings from the phase I clinical trial IAVI G001 showed that vaccination with the HIV immunogen eOD-GT8 60mer as a recombinant protein safely induced the targeted immune responses in 97% of recipients (healthy US adults). The immune response
